<DOC>
	<DOCNO>NCT02662712</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety data include serious adverse event , physical examination , vital sign , 12-lead electrocardiogram ( ECGs ) clinical laboratory result ( include biochemistry , hematology , urine ) .</brief_summary>
	<brief_title>A Study Orally Administered JNJ-56136379 Evaluate Safety , Tolerability Pharmacokinetics After Single Ascending Doses One Multiple Dose Regimen Healthy Participants ( Part I ) , After Multiple Dose Regimens Participants With Chronic Hepatitis B ( Part II )</brief_title>
	<detailed_description>Part 1 : This first-in-human ( FIH ) , double-blind ( neither researcher participant know treatment participant receiving ) , randomize ( study medication assign participant chance ) , placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) study . Part 1 include healthy adult participant , divide 3 panel ( Panel 1 , 2 3 ) Part 2 adult Chronic Hepatitis B Participants include , Sessions VIII XI Optional Sessions A-B-C ( Panel 4 ) . The study consist screen phase ( part 1 : [ le equal &lt; =28 day first intake study drug ; part 2 : [ &lt; =56 great equal { &gt; = } 20 day first intake study drug ) , Treatment Phase ( multiple dose phase part 1 : Day -1 12 19 day ; part 2 : 4 week ) Follow Phase ( part 1 : 30-35 day last study drug intake dropout ; part 2 : week 8 actual end study drug treatment ) . Participants ' safety evaluate throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>For Part II , female participant must nonchildbearing potential define : ) Postmenopausal : A postmenopausal state define menses 12 month without alternative medical cause . A high follicle stimulate hormone ( FSH ) level ( great ( &gt; ) 40 international unit per milliliter ( IU/L ) milliinternational unit per milliliter ( mIU/mL ) postmenopausal range may use confirm postmenopausal state woman use hormonal contraception hormonal replacement therapy , however absence 12 month amenorrhea , single FSH measurement insufficient b ) Permanently sterile : Permanent sterilization method include hysterectomy , bilateral salpingectomy , bilateral tubal occlusion/ligation procedure , bilateral oophorectomy Female participant negative serum pregnancy test screen Healthy Participants : Participants must body mass index ( BMI ; weight kg divide square height meter ) 18.0 30.0 kilogram per square meter ( kg/m2 ) , extremes include Chronic Hepatitis B Participants : Participants must lack advanced liver disease , ie , either : Metavir F0F2 ( comparable histologic score system ) determine liver biopsy within one year screen visit ; result base specific radiologic liver disease stag modality ( eg , Fibroscan , AFRI , magnetic resonance image [ MRI ] Elastography ) compatible Metavir F0F2 within 6 month screen visit Chronic Hepatitis B Participants : Participants must HBV DNA great equal [ &gt; = ] 2,000 international unit per milliliter ( IU/mL ) screen Chronic Hepatitis B Participants : Participants must age 18 year 65 year , body mass index ( BMI ; weight kg divide square height meter ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , extremes include Healthy Participants : Participants past history cardiac arrhythmia ( example , extrasystolic , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( eg , hypokalemia , family history long QT Syndrome ) Healthy Participants : Female participant breastfeed screen Healthy Participants : Participants current human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection ( confirmed antibody ) screen Chronic Hepatitis B Participants : Participants current HCV infection ( confirm HCV antibody HCV RNA ) hepatitis delta virus ( HDV ) infection ( confirm HDV antibody ) screen Chronic Hepatitis B Participants : Participants positivity antiHBs antibodies Chronic Hepatitis B Participants : Participants past history cardiac arrhythmia ( eg , extrasystolic , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( eg , hypokalemia , family history long QT Syndrome ) Chronic Hepatitis B Participants : Female participant breastfeed screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Hepatitis , Chronic</keyword>
	<keyword>JNJ-56136379</keyword>
	<keyword>Placebo</keyword>
</DOC>